SCP
RANI icon

SymBiosis Capital Partners’s Rani Therapeutics RANI Stock Holding History

SymBiosis Capital Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.69M Sell
3,667,585
-2,632,415
-42% -$3.36M 5.11% 4
2025
Q4 		$8.51M Buy
+6,300,000
New +$9.5M 7.77% 7

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SymBiosis Capital Partners's RANI Position: Q1 2026 in Review

SymBiosis Capital Partners reduced its Rani Therapeutics (RANI) stake by 42% in Q1 2026, selling an estimated $3.36M and leaving 3,667,585 shares worth $2.69M. The position accounts for 5.11% of the portfolio, ranked #4.

SymBiosis Capital Partners first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.51M in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • SymBiosis Capital Partners held 3,667,585 shares of Rani Therapeutics worth $2.69M as of Q1 2026.
  • SymBiosis Capital Partners sold 2,632,415 Rani Therapeutics shares in Q1 2026, an estimated $3.36M.
  • Rani Therapeutics made up 5.11% of SymBiosis Capital Partners's portfolio in Q1 2026, its #4 holding.
  • SymBiosis Capital Partners first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SymBiosis Capital Partners's Rani Therapeutics position peaked at $8.51M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.